Role of chromogenic in situ hybridization (CISH) in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH.
We report our experience with Chromogenic in Situ Hybridization (CISH) for the evaluation of HER2 amplification on 55 cases of formalin-fixed, paraffin-embedded invasive breast carcinomas of different histology. All the results were corrected for chromosome 17 aneusomy and compared with immunohistochemistry (IHC); a subset of cases was compared to FISH. Thirty-one of 32 cases in which FISH and CISH were performed yielded the same results. CISH and IHC showed a good concordance in the 0/1+ and 3+ category, while a poor agreement with weakly protein overexpression was confirmed. Chromosome 17 analysis was necessary in cases with a low number of HER2 gene copies. CISH is a useful tool to evaluate breast cancer HER2 status that can be easily implemented in a laboratory of surgical pathology.
Li-Ning-T
Elsa
E
Laboratory of Pathology, National Cancer Institute, Bethesda, MD 20892, USA.
Ronchetti
Ruben
R
Torres-Cabala
Carlos
C
Merino
Maria J
MJ
D001943:Breast Neoplasms / Q000737:chemistry* / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D044584:Carcinoma, Ductal / Q000737:chemistry / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D018275:Carcinoma, Lobular / Q000737:chemistry / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D002291:Carcinoma, Papillary / Q000737:chemistry / Q000175:diagnosis / Q000235:genetics / Q000473:pathology; D002863:Chromogenic Compounds; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods*; D017403:In Situ Hybridization / Q000379:methods*; D017404:In Situ Hybridization, Fluorescence / Q000379:methods*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis* / Q000235:genetics
D002863:Chromogenic Compounds; D018719:Erb-b2 Receptor Tyrosine Kinases